Table II.

Associations between selected SNPs in the Hippo pathway genes and CM-specific survival

	No.		Univariate analysis		Multivariate analysis*
	Patients	Death (%)	HR (95% CI)	P	HR (95% CI)	P
YAP1
rs11225163
CC	342	49 (14.33)	1.00		1.00
CT	394	36 (9.14)	0.63 (0.41–0.97)	0.035	0.55 (0.35–0.87)	0.010
TT	122	10 (8.20)	0.51 (0.26–1.00)	0.051	0.59 (0.30–1.18)	0.135
CT+TT	516	46 (8.91)	1.00		1.00
CC	342	49 (14.33)	1.67 (1.12–2.50)	0.012	1.79 (1.18–2.72)	0.007
TEAD1
rs7944031
AA	653	68 (10.41)	1.00		1.00
AG	185	25 (13.51)	1.34 (0.85–2.12)	0.211	1.81 (1.13–2.92)	0.014
GG	20	2 (10.00)	0.98 (0.24–4.00)	0.977	1.85 (0.45–7.56)	0.395
AA	653	68 (10.41)	1.00		1.00
AG+GG	205	27 (13.17)	1.31 (0.84–2.04)	0.243	1.82 (1.14–2.89)	0.012
TEAD4
rs1990330
CC	473	41 (8.67)	1.00		1.00
CA	332	46 (13.86)	1.60 (1.05–2.43)	0.029	1.51 (0.98–2.33)	0.065
AA	53	8 (15.09)	1.74 (0.81–3.71)	0.154	1.95 (0.90–4.43)	0.090
CC	473	41 (8.67)	1.00		1.00
CA+AA	385	54 (14.03)	1.62 (1.08–2.43)	0.021	1.56 (1.03–2.38)	0.037

SNPs = single nucleotide polymorphisms; CM = cutaneous melanoma; HR = hazards ratio.

^*Adjusted for age, sex, tumor stage, Breslow thickness, SLNB, 0. level, ulceration of tumor and tumor cell mitotic rate in the Cox models.